Kinins, airway obstruction, and anaphylaxis

Chemical Immunology and Allergy

Volumn 95, Issue , 2010, Pages 67-84

  Kaplan, Allen P ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBRINOLYTIC AGENT; ARGININE CARBOXYPEPTIDASE; BLOOD CLOTTING FACTOR 12; BRADYKININ; COMPLEMENT COMPONENT C1; COMPLEMENT COMPONENT C1S INHIBITOR; CONTRAST MEDIUM; CYTOKERATIN 1; DANAZOL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ECALLANTIDE; FRESH FROZEN PLASMA; HEAT SHOCK PROTEIN 90; HIGH MOLECULAR WEIGHT KININOGEN; ICATIBANT; IMMUNOGLOBULIN E; KININ; NONSTEROID ANTIINFLAMMATORY AGENT; OXYMETHOLONE; PREKALLIKREIN; STANOZOLOL;

AIRWAY OBSTRUCTION; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ASPHYXIA; CELL SURFACE; COMPLEMENT COMPONENT C1 INHIBITOR DEFICIENCY; COMPLEMENT DEFICIENCY; ENDOTHELIUM CELL; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HUMAN; IMMUNOPATHOGENESIS; MOLECULAR GENETICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW;

AIRWAY OBSTRUCTION; ANAPHYLAXIS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BLOOD COAGULATION; COMPLEMENT SYSTEM PROTEINS; ENDOTHELIAL CELLS; FACTOR XIA; HUMANS; KININS;

EID: 77954835000     PISSN: 16602242     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000315938     Document Type: Review

References (102)

1. Kaplan A, Silverberg M: Contact system and its disorders; in Handin R, Lux S, Stossel T (eds): Blood -Principles Practice of Hematology. Philadelphia, Lippincott Williams & Wilkins, 1995, pp 1131-1155.
2. Margolius H: Tissue kallikreins structure, regulation, and participation in mammalian physiology and disease. Clin Rev Allergy Immunol 1998;16:337-349.
3. Erdos E, Sloane G: An enzyme in human plasma that inactivates bradykinin and kallidins. Biochem Pharmacol 1962;11:585-592.
4. Sheikh IA, Kaplan AP: Studies of the digestion of bradykinin, lysyl bradykinin, and kinin-degradation products by carboxypeptidases A, B, and N. Biochem Pharmacol 1986;35:1957-1963.
5. Yang H, Erdos E: Second kininase in human blood plasma. Nature 1967;215:1402-1403.
6. Sheikh I, Kaplan A: Studies of the digestion of bradykinin, Lys-bradykinin, and des-arg-9 bradykinin by angiotensin-converting enzyme. Biochem Pharmacol 1986;35:1951-1956.
7. Regoli D, Barabe J: Pharmacology of bradykinin and related kinins. Pharmacol Rev 1980;32:1-46.
8. Marceau F: Kinin B1 receptors: a review. Immunopharmacology 1995;30:1-26.
9. Davis A, Perkins M: The involvement of bradykinin B1 and B2 receptor mechanisms in cytokineinduced mechanical hyperalgesia in the rat. Br J Pharmacol 1994;113:63-68.
10. Silverberg M, Dunn J, Garen L, Kaplan A: Autoactivation of human Hageman factor. Demonstration utilizing a synthetic substrate. J Biol Chem 1980;255: 7281-7286.
11. Tankersley DL, Finlayson JS: Kinetics of activation and autoactivation of human factor XII. Bio chemistry 1984;23:273-279.
12. Kaplan AP, Austen KF: A pre-albumin activator of prekallikrein. J Immunol 1970;105:802-811.
13. Mandle RJ, Kaplan A: Hageman factor substrates. Human plasma prekallikrein: mechanism of activation by Hageman factor and participation in Hageman factor-dependent fibrinolysis. J Biol Chem 1977;252:6097-6104.
14. Mandle R, Colman R, Kaplan A: Identification of prekallikrein and high-molecular-weight kininogen as a complex in human plasma. Proc Natl Acad Sci USA 1976;73:4179-4183.
15. Kerbiriou D, Griffin J: Human high molecular weight kininogen. Studies of structure-function relationships and of proteolysis of the molecule occurring during contact activation of plasma. J Biol Chem 1979;245:12020-12027.
16. Bock P, Shore J, Tans G, Griffin J: Protein-protein interactions in contact activation of blood coagulation. Binding of high molecular weight kininogen and the 5-(iodoacetamido)fluorescein-labeled kininogen light chain to prekallikrein, kallikrein, and the separated kallikrein heavy and light chains. J Biol Chem 1985;260:12434-12443.
17. Thompson RE, Mandle R Jr, Kaplan AP: Studies of binding of prekallikrein and factor XI to high molecular weight kininogen and its light chain. Proc Natl Acad Sci USA 1979;76:4862-4866.
18. Tait JF, Fujikawa K: Primary structure requirements for the binding of human high molecular weight kininogen to plasma prekallikrein and factor XI. J Biol Chem 1987;262:11651-11656.
19. Thompson RE, Mandle R Jr, Kaplan AP: Characterization of human high molecular weight kininogen. Procoagulant activity associated with the light chain of kinin-free high molecular weight kininogen. J Exp Med 1978;147:488-499.
20. Tait JF, Fujikawa K: Identification of the binding site for plasma prekallikrein in human high molecular weight kininogen. A region from residues 185-224 of the kininogen light chain retains full binding activity. J Biol Chem 1986;261:15396-15401.
21. Nakayasu T, Nagasawa S: Studies on human kininogens. I. Isolation, characterization, and cleavage by plasma kallikrein of high molecular weight kininogen. J Biochem 1979;85:249-258.
22. Mori K, Nagasawa S: Studies on human high molecular weight (HMW) kininogen. II. Structural change of HMW kininogen by the action of human plasma kallikrein. J Biochem 1981;89:1465-1473. (Pubitemid 11086511)
23. Reddigari S, Kaplan AP: Cleavage of human highmolecular-weight kininogen by purified kallikreins and upon contact activation of plasma. Blood 1988; 71:1334-1340.
24. Griffin JH: Role of surface in surface-dependent activation of Hageman factor (blood coagulation factor XII). Proc Natl Acad Sci USA 1978;75:1998-2002.
25. Silverberg M, Nicoll J, Kaplan A: The mechanism by which the light chain of cleaved HMW-kininogen augments the activation of prekallikrein, factor XI and Hageman factor. Thromb Res 1980;20:173-189.
26. Griffin JH, Cochrane CG: Mechanisms for the involvement of high molecular weight kininogen in surface-dependent reactions of Hageman factor. Proc Natl Acad Sci USA 1976;73:2554-2558.
27. Wiggins RC, Bouma BN, Cochrane CG, Griffin JH: Role of high-molecular-weight kininogen in surface-binding and activation of coagulation factor XI and prekallikrein. Proc Natl Acad Sci USA 1977;74: 4636-4640.
28. Cochrane CG, Revak SD: Dissemination of contact activation in plasma by plasma kallikrein. J Exp Med 1980;152:608-619.
29. Schmaier AH, Silver L, Adams AL, Fischer GC, Munoz PC, Vroman L, et al: The effect of high molecular weight kininogen on surface-adsorbed fibrinogen. Thromb Res 1984;33:51-67.
30. Schmaier AH, Kuo A, Lundberg D, Murray S, Cines DB: The expression of high molecular weight kininogen on human umbilical vein endothelial cells. J Biol Chem 1988;263:16327-16333.
31. Van Iwaarden F, de Groot PG, Bouma BN: The binding of high molecular weight kininogen to cultured human endothelial cells. J Biol Chem 1988; 263:4698-4703.
32. Nishikawa K, Shibayama Y, Kuna P, Calcaterra E, Kaplan AP, Reddigari SR: Generation of vasoactive peptide bradykinin from human umbilical vein endothelium-bound high molecular weight kininogen by plasma kallikrein. Blood 1992;80:1980-1988.
33. Reddigari SR, Kuna P, Miragliotta G, Shibayama Y, Nishikawa K, Kaplan AP: Human high molecular weight kininogen binds to human umbilical vein endothelial cells via its heavy and light chains. Blood 1993;81:1306-1311. (Pubitemid 23067369)
34. Reddigari SR, Shibayama Y, Brunnee T, Kaplan AP: Human Hageman factor (factor XII) and high molecular weight kininogen compete for the same binding site on human umbilical vein endothelial cells. J Biol Chem 1993;268:11982- 11987. (Pubitemid 23168160)
35. Joseph K, Ghebrehiwet B, Peerschke EI, Reid KB, Kaplan AP: Identification of the zinc-dependent endothelial cell binding protein for high molecular weight kininogen and factor XII: identity with the receptor that binds to the globular 'heads' of C1q (gC1q-R). Proc Natl Acad Sci USA 1996;93:8552-8557.
36. Herwald H, Dedio J, Kellner R, Loos M, Muller-Esterl W: Isolation and characterization of the kininogen-binding protein p33 from endothelial cells. Identity with the gC1q receptor. J Biol Chem 1996;271:13040-13047.
37. Hasan AA, Zisman T, Schmaier AH: Identification of cytokeratin 1 as a binding protein and presentation receptor for kininogens on endothelial cells. Proc Natl Acad Sci USA 1998;95:3615-3620.
38. Joseph K, Ghebrehiwet B, Kaplan AP: Cytokeratin 1 and gC1qR mediate high molecular weight kininogen binding to endothelial cells. Clin Immunol 1999;92:246-255.
39. Colman RW, Pixley RA, Najamunnisa S, Yan W, Wang J, Mazar A, et al: Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2 and 3 of the urokinase receptor. J Clin Invest 1997;100:1481-1487.
40. Joseph K, Tholanikunnel BG, Ghebrehiwet B, Kaplan AP: Interaction of high molecular weight kininogen binding proteins on endothelial cells. Thromb Haemost 2004;91:61-70.
41. Mahdi F, Shariat-Madar Z, Todd RF 3rd, Figueroa CD, Schmaier AH: Expression and colocalization of cytokeratin 1 and urokinase plasminogen activator receptor on endothelial cells. Blood 2001;97:2342-2350.
42. Motta G, Røkjæ R, Hasan AA, Cines DB, Schmaier AH: High molecular weight kininogen regulates prekallikrein assembly and activation on endothelial cells: a novel mechanism for contact activation. Blood 1998;91:516-528.
43. Røkjæ R, Hasan AA, Motta G, Schousboe I, Schmaier AH: Factor XII does not initiate prekallikrein activation on endothelial cells. Thromb Haemost 1998;80:74-81.
44. Schmaier AH: Contact activation: a revision. Thromb Haemost 1997;78:101-107.
45. Joseph K, Ghebrehiwet B, Kaplan AP: Activation of the kinin-forming cascade on the surface of endothelial cells. Biol Chem 2001;382:71-75.
46. Joseph K, Tholanikunnel B, Kaplan A: Heat-shock protein 90 catalyzes activation of the prekallikreinkininogen complex in the absence of factor XII. Proc Natl Acad Sci USA 2002;99:896-900.
47. Shariat-Madar Z, Mahdi F, Schmaier A: Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator. J Biol Chem 2002;277:17962-17969. (Pubitemid 34967607)
48. Schreiber A, Kaplan A, Austen K: Inhibition by C1INH of Hageman factor fragment activation of coagulation, fibrinolysis, and kinin generation. J Clin Invest 1973;52:1402-1409.
49. Pixley R, Schapira M, Colman R: The regulation of human factor XIIa by plasma proteinase inhibitors. J Biol Chem 1985;260:1723-1729.
50. Harpel P, Lewin M, Kaplan A: Distribution of plasma kallikrein between C-1 inactivator and α2-macroglobulin in plasma utilizing a new assay for α2-macroglobulin-kallikrein complexes. J Biol Chem 1985;260:4257-4263.
51. Donaldson V, Evans R: A biochemical abnormality in hereditary angioneurotic edema. Am J Med 1963; 35:37-44.
52. Kramer J, Katz Y, Rosen F, Davis AR, Strunk R: Synthesis of C1 inhibitor in fibroblasts from patients with type I and type II hereditary angioneurotic edema. J Clin Invest 1991;87:1614-1620.
53. Caldwell J, Ruddy S, Schur P, Austen K: Acquired C1 inhibitor deficiency in lymphosarcoma. Clin Immunol Immunopathol 1972;1:39-52.
54. Hauptmann G, Lang J, North M, Oberling F, Mayer G, Lachmann P: Acquired C1-inhibitor deficiencies in lymphoproliferative diseases with serum immunoglobulin abnormalities. A study of three cases. Blut 1976;32:195-206.
55. Schreiber A, Zweiman B, Atkins P, Goldwein F, Pietra G, Atkinson B, et al: Acquired angioedema with lymphoproliferative disorder: association of C1 inhibitor deficiency with cellular abnormality. Blood 1976;48:567-580.
56. Alsenz J, Bork K, Loos M: Autoantibody-mediated acquired deficiency of C1 inhibitor. N Engl J Med 1987;316:1360-1366.
57. Zuraw B, Curd J: Demonstration of modified inactive first component of complement (C1) inhibitor in the plasmas of C1 inhibitor-deficient patients. J Clin Invest 1986;78:567-575.
58. Malbran A, Hammer C, Frank M, Fries L: Acquired angioedema: observations on the mechanism of action of autoantibodies directed against C1 esterase inhibitor. J Allergy Clin Immunol 1988;81:1199-1204.
59. Pearson K, Buchignani J, Shimkin P, Frank M: Hereditary angioneurotic edema of the gastrointestinal tract. Am J Roetgenol Radium Ther Nucl Med 1972;116:256-261.
60. Tosi M: Molecular genetics of C1 inhibitor. Immunobiology 1998;119:358-365.
61. Quastel M, Harrison R, Cicardi M, Alper C, Rosen F: Behavior in vivo of normal and dysfunctional C1 inhibitor in normal subjects and patients with hereditary angioneurotic edema. J Clin Invest 1983; 71:1041-1046.
62. Kramer J, Rosen F, Colten H, Rajczy K, Strunk R: Transinhibition of C1 inhibitor synthesis in type I hereditary angioneurotic edema. J Clin Immunol 1993;91:1258-1262.
63. Ruddy S, Gigli I, Sheffer A, Austen K: The laboratory diagnosis of hereditary angioedema; in Rose N, Richter M, Sehon A (eds): Proceedings of the Sixth International Congress of Allergology. Amsterdam, Excerpta Medica, 1968, pp 351-359.
64. Zuraw B, Sugimoto S, Curd J: The value of rocket immunoelectrophoresis for C4 activation in the evaluation of patients with angioedema or C1-inhibitor deficiency. J Allergy Clin Immunol 1986;78:1115-1120.
65. Austen KF, Sheffer AL: Detection of hereditary angioneurotic edema by demonstration of a reduction in the second component of human complement. N Engl J Med 1965;272:649-656.
66. Ichinose A, Fujikawa K, Suyama T: The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. J Biol Chem 1986;261:3486-3489.
67. Fields T, Ghebrehiwet B, Kaplan AP: Kinin formation in hereditary angioedema plasma: evidence against kinin derivation from C2 and in support of 'spontaneous' formation of bradykinin. J Allergy Clin Immunol 1983;72:54-60.
68. Curd J, Yelvington M, Burridge N: Generation of bradykinin during incubation of hereditary angioedema plasma. Mol Immunol 1983;19:1365.
69. Curd J, Prograis LJ, Cochrane C: Detection of active kallikrein in induced blister fluids of hereditary angioedema patients. N Engl J Med 1980;152:742-747.
70. Juhlin L, Michaelsson G: Vascular reactions in hereditary angioneurotic edema. Acta Derm Venereol 1969;40:20-25.
71. Schapira M, Silver L, Scott C, Schmaier A, Prograis LJ, Curd J, et al: Prekallikrein activation and high-molecular-weight kininogen consumption in hereditary angioedema. N Engl J Med 1983;308: 1050-1053.
72. Cugno M, Cicardi M, Coppola R, Agostoni A: Activation of factor XII and cleavage of high molecular weight kininogen during acute attacks in hereditary and acquired C1-inhibitor deficiencies. Immunopharmacology 1996;33:361-364.
73. Nussberger J, Cugno M, Cicardi M, Agostoni A: Local bradykinin generation in hereditary angioedema. J Allergy Clin Immunol 1999;104:1321-1322.
74. Donaldson VH: Mechanisms of activation of C'1 esterase in hereditary angioneurotic edema plasma in vitro. J Exp Med 1968;127:411-429.
75. Ratnoff OD, Naff GB: The conversion of ĆIS to Ć1 esterase by plasmin and trypsin. J Exp Med 1967; 125:337-358.
76. Ghebrehiwet B, Silverberg M, Kaplan AP: Activation of the classical pathway of complement by Hageman factor fragment. J Exp Med 1981;153:665-676.
77. Ghebrehiwet B, Randazzo B, Dunn J, Silverberg M, Kaplan A: Mechanisms of activation of the classical pathway of complement by Hageman factor fragment. J Clin Invest 1983;71:1450-1456.
78. Zahedi R, Bissler J, Davis AR, Andreadis C, Wisnieski J: Unique C1 inhibitor dysfunction in a kindred without angioedema. II. Identification of an Ala443→Val substitution and functional analysis of the recombinant mutant protein. J Clin Invest 1995;95:1299-1305.
79. Zahedi R, Wisnieski J, Davis AE 3rd: Role of the P2 residue of complement-1 inhibitor (Ala443) in determination of target protease specificity: inhibition of complement and contact system proteases. J Immunol 1997;159:983-988.
80. Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A: Plasma bradykinin in angioedema. Lancet 1998;351:1693-1697.
81. Han E, MacFarlane R, Mulligan A, Scafidi J, Davis AR: Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest 2002;8:1057-1063.
82. Kaplan AP, Austen KF: A prealbumin activator of prekallikrein. II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin. J Exp Med 1971;133:696-712.
83. Wallace EM, Perkins SJ, Sim RB, Willis AC, Feighery C, Jackson J: Degradation of C1 inhibitor by plasmin: implications for the control of inflammatory processes. Mol Med 1997;3:385-396.
84. Geha R, Quinti I, Austen K, Cicardi M, Sheffer A, Rosen F: Acquired C1-inhibitor deficiency associated with anti-idiotypic antibody to monoclonal immunoglobulins. N Engl J Med 1985;312:534-540.
85. Donaldson V, Hess E, McAdams A: Lupus-erythematosus-like disease in three unrelated women with hereditary angioneurotic edema. Ann Intern Med 1977;86:312-313.
86. Cohen S, Koethe S, Kozin F, Rodey G, Arkins J, Fink J: Acquired angioedema associated with rectal carcinoma and its response to danazol therapy. Acquired angioedema treated with danazol. J Allergy Clin Immunol 1978;62:217-221.
87. Jackson J, Sim R, Whelan A, Feighery C: An IgG autoantibody which inactivates C1-inhibitor. Nature 1986;323:722-724.
88. Jackson J, Sim R, Whaley K, Feighery C: Autoantibody facilitated cleavage of C1-inhibitor in autoimmune angioedema. J Clin Invest 1989;83:698-707.
89. He S, Sim R, Whaley K: Mechanism of action of anti-C1-inhibitor autoantibodies: prevention of the formation of stable C1s-C1-inh complexes. Mol Med 1998;4:119-128.
90. Bas M, Bier H, Greve J, Kojda G, Hoffmann T: Novel pharmacotherapy of acute hereditary angioedema with bradykinin B2-receptor antagonist icatibant. Allergy 2006;61:1490-1492.
91. Bork K, Frank J, Grundt B, Schlattmann P, Nussberger J, Kreuz W: Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (icatibant). J Allergy Clin Immunol 2007;119:1497-1503.
92. Schneider L, Lumry W, Vegh A, Williams A, Schmalbach T: Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor. J Allergy Clin Immunol 2007;120:416-422.
93. Binkley K, Davis AR: Clinical, biochemical, and genetic characterization of a novel estrogen-dependent inherited form of angioedema. J Allergy Clin Immunol 2000;106:546-550.
94. Dewald G, Bork K: Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem Biophys Res Commun 2006;343:1286-1289.
95. Martin L, Raison-Peyron N, Nothen M, Cichon S, Drouet C: Hereditary angioedema with normal C1 inhibitor gene in a family with affected women and men is associated with the p.Thr328Lys mutation in the F12 gene. J Allergy Clin Immunol 2007;120:975-977.
96. Kaplan A, Greaves M: Angioedema. J Am Acad Dermatol 2005;53:373-388.
97. Byrd J, Shreevatsa A, Putlur P, Foretia D, McAlexander L, Sinha T, et al: Dipeptidyl peptidase IV deficiency increases susceptibility to angiotensinconverting enzyme inhibitor-induced peritracheal edema. J Allergy Clin Immunol 2007;120:403-408.
98. Sheikh IA, Kaplan AP: Mechanism of digestion of bradykinin and lysylbradykinin (kallidin) in human serum. Role of carboxypeptidase, angiotensinconverting enzyme and determination of final degradation products. Biochem Pharmacol 1989;38: 993-1000.
99. Schulman G, Hakim R, Arias R, Silverberg M, Kaplan AP, Arbeit L: Bradykinin generation by dialysis membranes: possible role in anaphylactic reaction. J Am Soc Nephrol 1993;3:1563-1569.
100. Alving BM, Hojima Y, Pisano JJ, Mason BL, Buckingham RE Jr, Mozen MM, et al: Hypotension associated with prekallikrein activator (Hageman-factor fragments) in plasma protein fraction. N Engl J Med 1978;299:66-70.
101. Kishimoto T, Viswanathan K, Ganguly T, Elankumaran S, Smith S, Pelzer K, et al: Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 2008; 358:2457-2467. (Pubitemid 351793019)
102. Smith P, Kagey-Sobotka A, Bleecker E, Traystman R, Kaplan A, Gralnick H, et al: Physiologic manifestations of human anaphylaxis. J Clin Invest 1980; 66:1072-1080.